Cullinan Therapeutics, Inc. (CGEM)

Market Cap	675.44M
Revenue (ttm)	n/a
Net Income (ttm)	-143.54M
Shares Out	58.23M
EPS (ttm)	-2.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	799,893
Open	10.86
Previous Close	10.95
Day's Range	10.78 - 11.86
52-Week Range	9.24 - 30.19
Beta	-0.17
Analysts	Strong Buy
Price Target	31.67 (+173.02%)
Earnings Date	Nov 7, 2024

About CGEM

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company’s lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for t...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 8, 2021
• Employees: 85
• Stock Exchange: NASDAQ
• Ticker Symbol: CGEM
• Website: https://cullinantherapeutics.com

Analyst Forecast

According to 7 analysts, the average rating for CGEM stock is "Strong Buy." The 12-month stock price forecast is $31.67, which is an increase of 173.02% from the latest price.

Price Target

$31.67

(173.02% upside)

Analyst Consensus: Strong Buy